(All figures are presented in U.S. Dollars) Adjusted EBITDA 1 in Q3 2025 was $7.3 million , an increase of 79% over Q3 2024 Natroba TM sales were $8.1 million during the quarter, a sequential increase of 4% over Q2 2025 Strong cash generation with $10.8 million cash from operations in Q3 2025 $12.0 million debt repayments and share repurchases of $1.6 million during Q3 2025 Further de-levering with $5.0 million debt... Read More

MISSISSAUGA, ON , Oct. 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc . (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") today announced that it will release its financial results for the third quarter of 2025 after the market close on Thursday, November 6, 2025 . The Company will also hold a conference call on Friday, November 7, 2025 at 8:30am ET to discuss the results and corporate developments. CONFERENCE CALL... Read More

MISSISSAUGA, ON , Oct. 14, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") has received a favourable award from an extensive and comprehensive arbitration proceeding, related to a contractual dispute with Sun Pharmaceuticals Industries, Inc. (" Sun ") regarding Sun's breach of certain provisions of its supply and distribution agreement with the Company (the " Agreement ").... Read More

MISSISSAUGA, ON , Aug. 26, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") announces with great sadness the passing of Harold M. Wolkin , a valued member of the Company's Board of Directors (the "Board") and Chairman of the Audit Committee. Mr. Wolkin was a very active member of the Board and his deep understanding of the capital markets and unwavering commitment to the... Read More

Highest single-quarter revenue in the Company's history with total revenue of $13.4 million in Q2 2025 Adjusted EBITDA 1 in Q2 2025 was $7.6 million , an increase of 148% over Q2 2024 Epuris sales volumes grew 14% in the quarter compared to Q2 2024 Natroba TM sales were $7.8 million during the quarter, a sequential increase of 16% over Q1 2025 Strong cash generation with $6.0 million cash from operations in Q2 2025 $15.0... Read More

MISSISSAUGA, ON , July 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") today announced that it will release its financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025 . The Company will also hold a conference call on Friday, August 8, 2025 at 8:30am ET to discuss the results and corporate developments. CONFERENCE CALL DETAILS... Read More

MISSISSAUGA, ON , June 13, 2025 /CNW/ - Cipher Pharmaceuticals Inc . (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the "Company ") announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company's management information circular dated May 2, 2025 were approved by the requisite majority of votes cast at... Read More

(All figures are presented in U.S. Dollars) Adjusted EBITDA 2 in Q1 2025 was $6.2 million , an increase of 73% over Q1 2024 Canadian product portfolio sales volumes grew 46% in the quarter compared to Q1 2024 Natroba TM sales were $6.7 million during the quarter, a sequential increase of 3% over Q4 2024 Continued strong track record of cash generation with $4.2 million cash from operations in Q1 2025 $22.0 million cash... Read More

MISSISSAUGA, ON , May 2, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") today announced that it will release its financial results for the first quarter of 2025 after the market close on Thursday, May 8, 2025 . The Company will also hold a conference call on Friday, May 9, 2025 at 8:30am ET to discuss the results and corporate developments. CONFERENCE CALL DETAILS DATE:... Read More

MISSISSAUGA, ON , May 1, 2025 /CNW/ - Cipher Pharmaceuticals Inc . (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or " the Company ") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to commence a normal course issuer bid ("NCIB") for its common shares (the "Common Shares"). The TSX notice provides that Cipher may, during the 12-month period commencing May 5,... Read More

MISSISSAUGA, ON , April 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") proudly announces the state of Illinois has updated its Preferred Drug Listing ("PDL") where Cipher's product Natroba™, for the treatment of scabies and head lice, has obtained preferred drug status on Medicaid state plans, and whereby its main competitive product Permethrin 5% has been downgraded to... Read More

(All figures are presented in U.S. Dollars) Generated $8.3 million in cash during Q4 2024 Natroba™ revenue was $12.0 million for the 5 months of fiscal 2024 since acquisition Full year adjusted EBITDA 1 of $15.7 million , an increase of 23% over fiscal 2023 Cash at December 31, 2024 was $17.8 million or $0.70 per outstanding common share Epuris revenue grew by 20% in fiscal 2024 compared to fiscal 2023 Reactivation of a... Read More

MISSISSAUGA, ON , March 11, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") today announced that it will release its financial results for the fourth quarter and fiscal 2024 after the market close on Tuesday, March 18, 2025 . The Company will also hold a conference call on Wednesday, March 19, 2025 at 8:30am ET to discuss the results and corporate developments. CONFERENCE... Read More

MISSISSAUGA, ON , Dec. 10, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that MOB-015, a product for the treatment of nail fungus, did not meet the primary endpoint in the North American Phase 3 study being conducted by Moberg. The results of the North American Phase... Read More

(All figures are presented in U.S. Dollars) Successfully closed the acquisition of the U.S. based Natroba™ business on July 26, 2024 Epuris sales volumes grew 29% compared to Q3 2023, continuing growth trajectory for the fifth consecutive quarter Strong product gross margin from the acquired Natroba products of 85% Added management depth with appointment of Dr. Hamed Ghanei , Chief Business Officer MISSISSAUGA, ON , Nov. 7,... Read More

MISSISSAUGA, ON , Nov. 4, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") today announced that it will release its financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024 . The Company will also hold a conference call on Friday, November 8, 2024 at 8:30am ET to discuss the results and corporate developments. CONFERENCE CALL... Read More

MISSISSAUGA, ON , Oct. 8, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") announced today the appointment of Hamed Ghanei as Chief Business Officer ("CBO"). Craig Mull , Interim Chief Executive Officer, commented on the appointment: "I am delighted to announce the addition of Dr. Ghanei to Cipher's executive team. Hamed's expertise in business development, including... Read More

MISSISSAUGA, ON / ACCESSWIRE / September 24, 2024 / Cipher Pharmaceuticals Inc (TSX:CPH) (OTCQX:CPHRF) ("Cipher") today announced that it will be presenting and participating in 1x1 meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in association with Small Cap Discoveries on Thursday, September 26, 2024, at 9AM (Local Time - PST). Interim Chief Executive Officer Craig Mull will be hosting the presentation and... Read More

MISSISSAUGA, ON , Sept. 13, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015, a product for the treatment of nail fungus. Moberg has noted... Read More

(All figures are presented in U.S. Dollars) Adjusted EBITDA was $3.1 million in Q2 2024, consistent with Q2 2023 Epuris sales volumes grew 13% compared to Q2 2023, continuing its growth trajectory for the fourth consecutive quarter Strong operating cash flows of $6.2 million in Q2 2024 Management changes to take effect on August 10, 2024 : CFO Bryan Jacobs to transition to President, focusing on the U.S. operations Vice... Read More

MISSISSAUGA, ON , Aug. 1, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") today announced that it will release its financial results for the second quarter of 2024 after the market close on Thursday, August 8, 2024 . The Company will also hold a conference call on Friday, August 9, 2024 at 8:30AM ET to discuss the results and corporate developments. CONFERENCE CALL DETAILS... Read More

MISSISSAUGA, ON , July 29, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") announces the signing of a definitive asset purchase agreement with ParaPRO LLC ("ParaPRO") and the closing of the acquisition of the global product rights for Natroba™ (Spinosad), as well as the commercial sales team in the United States for total consideration of US$89.5 million . Acquisition... Read More

MISSISSAUGA, ON , June 14, 2024 /CNW/ - Cipher Pharmaceuticals Inc . (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the "Company ") today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company's management information circular dated May 3, 2024 were approved by the requisite majority of votes... Read More

Adjusted EBITDA in Q1 2024 was $3.6 million , an increase of 12.5% over Q1 2023 Epuris sales volumes grew 7.2% in the quarter over Q1 2023, continuing growth trajectory for the third consecutive quarter Licensing revenue increased 55.1% to $2.6 million over Q1 2023 Cash at March 31, 2024 was $42.0 million ( CDN$56.9 million ) or $1.74 per outstanding common share (CDN$2.36) (All figures are presented in U.S. Dollars)... Read More

MISSISSAUGA, ON , May 3, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") today announced that it will release its financial results for the first quarter of 2024 after the market close on Thursday, May 9, 2024 . The Company will also hold a conference call on Friday, May 10, 2024 at 8:30 ET to discuss the results and corporate developments. CONFERENCE CALL DETAILS DATE: May... Read More

Mississauga, Ontario--(Newsfile Corp. - April 3, 2024) - Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre . Dates: Tuesday April 16, 2024-Wednesday April 17, 2024 Time: 8:30 AM-5:00 PM ET Location: Metro Toronto Convention Centre, North Building 255 Front St W... Read More